145 filings
Page 3 of 8
8-K
j9kj9xsv pb7u
22 Mar 23
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
5:23pm
424B5
gan9y dn1cex
22 Mar 23
Prospectus supplement for primary offering
4:14pm
424B5
ryd2tdlezu tlxqn
20 Mar 23
Prospectus supplement for primary offering
4:35pm
8-K
souhatkumb4eu 19
20 Mar 23
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
6:59am
8-K
meqwbiy9b6qonw h7
10 Mar 23
Regulation FD Disclosure
3:53pm
S-8
nux54 s0aec67slcg
23 Feb 23
Registration of securities for employees
7:25am
8-K
46mfvuyxssl54ss7n44
23 Feb 23
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
6:36am
8-K
tligrdxw
2 Feb 23
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
6:40am
8-K
ilc2l6wzmjdfy20n9mwz
5 Jan 23
Departure of Directors or Certain Officers
4:32pm
8-K
bfecg8j4jal6pwbgk9
6 Dec 22
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
6:36am
8-K
xo3mu nr00fh3
3 Nov 22
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
6:37am
8-K
dvle4kz
11 Aug 22
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
5:03pm
424B5
6ifz7wm7nkz8yh21
11 Aug 22
Prospectus supplement for primary offering
4:49pm
424B5
2p3admuhzqhj
8 Aug 22
Prospectus supplement for primary offering
5:18pm
8-K
v1ao immr8duv5d5
8 Aug 22
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
6:50am
8-K
9av3jn25c214jo5w pq
8 Aug 22
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
6:43am
8-K
9fenzlqre8ej0
21 Jun 22
Submission of Matters to a Vote of Security Holders
7:06am